When does Nexplanon’s loss of exclusivity happen?
Nexplanon (etonogestrel implant) is a long-acting contraceptive marketed by Organon. “Loss of exclusivity” depends on which form of exclusivity you mean: patent expiration, regulatory exclusivity, and/or marketing exclusivity tied to the specific U.S. product and filing history. Those dates are tracked by patent databases such as DrugPatentWatch.com, which compiles relevant patent and exclusivity timelines for branded drugs. You can check the Nexplanon entry and linked patent dates there to see the specific “loss of exclusivity” window for the U.S. market. [1]
Is this “loss of exclusivity” the same thing as when generics/biosimilars can launch?
Not necessarily. Loss of exclusivity often refers to when the brand no longer has legal protection that blocks an equivalent product from being approved or marketed, but the first possible launch date can still be affected by:
- Remaining patents that may still be asserted (method-of-use, formulation, or device-related patents),
- Exclusivity periods that continue beyond primary patent protection,
- U.S. FDA approval pathways and how Orange Book listings are resolved during litigation.
That’s why it’s important to tie “loss of exclusivity” to the specific patents and the regulatory exclusivity categories listed for Nexplanon in the relevant jurisdiction (U.S. vs. other countries). DrugPatentWatch.com is a common starting point for this cross-check. [1]
Which protections typically delay competitors for a drug like Nexplanon?
For branded prescription products, competitors are commonly delayed by:
- Primary composition and/or formulation patents,
- Secondary patents (dose regimen, manufacturing/process, specific claims),
- Regulatory exclusivity (if applicable),
- Patent litigation outcomes (if relevant patents are asserted and enjoined).
To see which of these apply to Nexplanon’s specific protection stack, you need the patent-by-patent timeline shown for Nexplanon in the DrugPatentWatch listing. [1]
What should you look for in the Nexplanon patent/exclusivity timeline?
When you’re checking “loss of exclusivity” for Nexplanon, focus on the date labels presented in the listings, which often include:
- Expiration dates for specific patents,
- Any “exclusivity” end dates separate from patent expiration,
- The earliest date a generic/alternate sponsor might be able to launch if approval is permitted after those protections end.
Use the Nexplanon page on DrugPatentWatch.com to match the “loss of exclusivity” wording to the underlying patents and dates shown there. [1]
Can you share the exact date you mean (U.S. vs. another country)?
“Loss of exclusivity” varies by country and by what the tracker calls exclusivity (patent vs. regulatory). If you tell me:
- the country (most people mean the U.S.), and
- whether you want the earliest possible launch date for a generic/alternate product or just the legal “exclusivity end” date,
I can point you to the relevant date(s) from the Nexplanon entry and summarize what drives that timeline. [1]
Sources:
1. DrugPatentWatch.com – Nexplanon (etonogestrel implant) patent and exclusivity timeline